Table 1 Baseline participant characteristics by study group
Characteristic | Active product | Control product |
|---|---|---|
(n = 265) | (n = 262) | |
Demographics | ||
Age (years) | 76.6 (8.2) | 76.9 (8.2) |
Female | 139 (52%) | 135 (52%) |
Education after finishing primary school | 6.7 (3.6) | 6.4 (3.5) |
White (including Hispanic) | 250 (94%) | 247 (94%) |
Mean time from initial AD diagnosis (months) | 32.7 (25.0) | 34.9 (29.6) |
Duration of AD medication use (months) | 28.8 (22.9) | 31.5 (28.7) |
Type of AD medication used | ||
Acetylcholinesterase inhibitor | 87 (32.8%) | 92 (35.1%) |
Memantine | 13 (4.9%) | 19 (7.3%) |
Acetylcholinesterase inhibitor and memantine combined | 164 (61.9%) | 151 (57.6%) |
Body mass index (kg/m2) | 26.2 (4.5) | 26.6 (4.6) |
Mini-Mental State Examination score (out of 30) | 19.5 (3.2) | 19.4 (3.0) |
Presence of apolipoprotein E ϵ4 allele | ||
No | 87 (39.2%) | 84 (42.0%) |
Yes | 135 (60.8%) | 116 (58.0%) |
Unknown | 43 | 62 |